Precision Therapeutics, NAAF to provide patient registry for alopecia areata
Precision Therapeutics announced a services agreement between its wholly owned subsidiary, Helomics and the National Alopecia Areata Foundation, or NAAF, which serves the community of people affected by an autoimmune skin disease called alopecia areata that results in hair loss and emotional pain, to provide a patient registry to drive research into new treatments for people with this disease. Helomics will leverage its CRO and Biorepository services offering to provide storage, processing and analysis of samples from patients with alopecia areata who newly enroll with the NAAF registry, as well as storing samples from the existing registry. The companies will also explore the application of the Helomics D-CHIP artificial intelligence platform to data generated as part of the registry. Terms and financial conditions of the agreement were not disclosed.